What Do We Measure in Oncology PET?

Kyoungjune Pak; Seong-Jang Kim

doi:10.1007/s13139-016-0416-y

What Do We Measure in Oncology PET?

Nucl Med Mol Imaging. 2017 Sep;51(3):212-216. doi: 10.1007/s13139-016-0416-y. Epub 2016 Apr 18.

Authors

Kyoungjune Pak¹, Seong-Jang Kim^{1

2}

Affiliations

¹ Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
² Department of Nuclear Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University, Yangsan, Korea.

Abstract

Positron emission tomography (PET) has come to the practice of oncology. It is known that ¹⁸F-fluorodeoxyglucose (FDG) PET is more sensitive for the assessment of treatment response than conventional imaging. In addition, PET has an advantage in the use of quantitative analysis of the study. Nowadays, various PET parameters are adopted in clinical settings. In addition, a wide range of factors has been known to be associated with FDG uptake. Therefore, there has been a need for standardization and harmonization of protocols and PET parameters. We will introduce PET parameters and discuss major issues in this review.

Keywords: Computer-assisted image processing; Medical oncology; Positron-emission tomography; Radiopharmaceuticals.

Publication types

Review